Jiangsu Bioperfectus Technologies Co Ltd
SSE:688399
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its 3-Year Average (27.4), the stock would be worth ¥4.49 (93% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 369.7 | ¥60.7 |
0%
|
| 3-Year Average | 27.4 | ¥4.49 |
-93%
|
| 5-Year Average | 14.3 | ¥2.35 |
-96%
|
| Industry Average | 28.7 | ¥4.72 |
-92%
|
| Country Average | 28.8 | ¥4.73 |
-92%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
Jiangsu Bioperfectus Technologies Co Ltd
SSE:688399
|
5.1B CNY | 369.7 | -196.1 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.8T JPY | 47.1 | 39.3 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
57B USD | 0 | 0 | |
| CH |
|
Alcon AG
SIX:ALC
|
28.2B CHF | 23.6 | 35.6 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
89.7B DKK | 20.4 | 22.4 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
12.7B USD | 23.7 | 31 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.1B GBP | 24.2 | 31.2 | |
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
38B CNY | 31.8 | 23 | |
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
875B JPY | 24.6 | 49.5 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
8.3T KRW | -75.9 | -37.9 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.4B USD | -152.6 | -15 |
Market Distribution
| Min | 0 |
| 30th Percentile | 14.5 |
| Median | 28.8 |
| 70th Percentile | 57 |
| Max | 307 555.7 |
Other Multiples
Jiangsu Bioperfectus Technologies Co Ltd
Glance View
Jiangsu Bioperfectus Technologies Co., Ltd. engages in the research, development, production, and sale of in vitro diagnostic reagents and supporting testing instruments. The company is headquartered in Taizhou, Jiangsu and currently employs 765 full-time employees. The company went IPO on 2019-12-05. The firm's products mainly include in vitro diagnostic reagents, supporting testing instruments and in vitro testing services. Its products are mainly used in the fields of infectious disease prevention and control, clinical testing, large-scale population screening, as well as prenatal and postnatal care management. The firm mainly conducts its businesses in domestic and overseas markets.
